cerlapirdine
≈ 1 min read
Names in other languages
- Englishcerlapirdine
- shCerlapirdin
- СрпскиCerlapirdin
- azbسرلاپیردین
- فارسیسرلاپیردین
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which was under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia. In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events, but no further development has occurred since 2011.
It exerts its effects by acting as a selective 5-HT 6 receptor antagonist.
Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which was under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia. In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events, but no further development has occurred since 2011.
It exerts its effects by acting as a selective 5-HT 6 receptor antagonist.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1357689306 under CC BY-SA 4.0; modifications have been made.